News

Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program

  • SAN DIEGO , Feb. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Board of Directors has authorized a new share repurchase program under which Neurocrine Biosciences may repurchase up to $500 million of its shares, subject to market conditions. This new share repurchase authorization is in addition to the $300 million accelerated repurchase program that was announced in October 2024 and completed in early February 2025.
    02/21/2025

Why Neurocrine Biosciences Stock Sank Today

  • Despite better-than-expected profitability in the fourth quarter, which it reported late last week, Neurocrine Biosciences (NBIX -3.11%) hasn't been wowing analysts lately. On Monday, no less than three of them lowered their price targets on the biotech's shares, leaving them with a more than 3% loss in price on the day.
    02/10/2025
Profitability
Responsive image
Dividends
Responsive image
Income Statement
Responsive image
Balance Sheet
Responsive image
Cash Flow Statement
Responsive image
Symbol Frequently Asked Questions

Neurocrine Biosciences, Inc. (NBIX) can buy. Click on Rating Page for detail.

The price of Neurocrine Biosciences, Inc. (NBIX) is 116.545 and it was updated on 2025-02-25 09:00:19.

Currently Neurocrine Biosciences, Inc. (NBIX) is in undervalued.

Analysis
    
News
    
SEC Filings
Press Releases
More Headlines
Unlock
NBIX Ratings Summary
Quant
NBIX Quant Ranking
Sector
Industry
Quant Rating
Quant Score